Kurt Graves takes top spot at i2o

i2o Therapeutics Inc. named Executive Chairman Kurt Graves as chairman, president and CEO. He succeeds co-founder and CEO Ravi Srinivasan, who is leaving to pursue other opportunities. Graves was chairman, president and CEO of Intarcia Therapeutics Inc., from which i2o acquired cardio-metabolic pipeline assets. i2o is using ionic liquids to develop oral biologics and peptides, and has raised $46 million in series A funding.

Immuno-oncology company Genelux Corp. (NASDAQ:GNLX) hired Lourie Zak as CFO. Zak was CFO at Guitar Center Inc., Sonifi Solutions Inc., and PBS Biotech Inc. Former CFO Doug Samuelson, who held the role when Genelux went public this year, will resume his prior position as VP of finance...